Chris Anthony
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chris Anthony has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Allan L. Klein
Cleveland Clinic
2 shared publications - Reza Reyaldeen
Section of Cardiovascular Imaging, Heart, Vascular and Thoracic Institute Cleveland Clinic Cleveland Ohio USA
2 shared publications - Ahmad Mustafa
Northwell, New Hyde Park, New York, USA
1 shared publication - Ahmed Abdel Khalek Abdel Razek
Department of Diagnostic Radiology, Mansoura Faculty of Medicine, Mansoura University, Mansoura, Egypt
1 shared publication Ajay Sharma
1 shared publication- Andrew Jabbour
School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Kensington, NSW 2052, Australia
1 shared publication
Latest Publications
- 1 January 2022
- Published by Elsevier
List of contributors
- Open Access
- 5 October 2021
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 10 (19) , e021685
Emerging Therapies for Recurrent Pericarditis: Interleukin‐1 inhibitors
Recurrent pericarditis (RP) is a complex inflammatory disorder associated with adverse outcomes and poor quality of life. After the first episode of acute pericarditis, a non‐negligible group of patients will fail to achieve complete remission despite treatment and will be challenged by side effects from the chronic use of medications like corticosteroids. The cause of RP remains unknown in the majority of cases, mainly due to a gap in knowledge of its complex pathophysiology. Over the past 2 decades, the interleukin‐1 (IL‐1) pathway has been uncovered as a key element in the inflammatory cascade, allowing the development of pharmacological targets known as IL‐1 inhibitors. This group of medications has emerged as a treatment option for patients with RP colchicine‐resistance and steroid dependents. Currently, anakinra and rilonacept, have demonstrated beneficial impact in clinical outcomes with a reasonable safety profile in randomized clinical trials. There is still paucity of data regarding the use of canakinumab in the treatment of patients with RP. Although further studies are needed to refine therapeutic protocols and taper of concomitant therapies, IL‐1 inhibitors, continue to consolidate as part of the pharmacological armamentarium to manage this complex condition with potential use as monotherapy. The aim of this review is to highlight the role of IL‐1 pathway in RP and discuss the efficacy, safety, and clinical applicability of IL‐1 inhibitors in the treatment of RP based on current evidence.
- 5 October 2021
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 10 (19) , e021685
Open AccessEmerging Therapies for Recurrent Pericarditis: Interleukin‐1 inhibitors
Recurrent pericarditis (RP) is a complex inflammatory disorder associated with adverse outcomes and poor quality of life. After the first episode of acute pericarditis, a non‐negligible group of patients will fail to achieve complete remission despite treatment and will be challenged by side effects from the chronic use of medications like corticosteroids. The cause of RP remains unknown in the majority of cases, mainly due to a gap in knowledge of its complex pathophysiology. Over the past 2 decades, the interleukin‐1 (IL‐1) pathway has been uncovered as a key element in the inflammatory cascade, allowing the development of pharmacological targets known as IL‐1 inhibitors. This group of medications has emerged as a treatment option for patients with RP colchicine‐resistance and steroid dependents. Currently, anakinra and rilonacept, have demonstrated beneficial impact in clinical outcomes with a reasonable safety profile in randomized clinical trials. There is still paucity of data regarding the use of canakinumab in the treatment of patients with RP. Although further studies are needed to refine therapeutic protocols and taper of concomitant therapies, IL‐1 inhibitors, continue to consolidate as part of the pharmacological armamentarium to manage this complex condition with potential use as monotherapy. The aim of this review is to highlight the role of IL‐1 pathway in RP and discuss the efficacy, safety, and clinical applicability of IL‐1 inhibitors in the treatment of RP based on current evidence.
- Open Access
- 8 November 2020
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 29, S38-S39
004 Cardiovascular Magnetic Resonance for Rejection Surveillance After Cardiac Transplantation
- 8 November 2020
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 29, S38-S39
Open Access004 Cardiovascular Magnetic Resonance for Rejection Surveillance After Cardiac Transplantation